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Patients undergoing primary chemotherapy for invasive breast cancer consented to a core biopsy of the invasive breast primary pre-
and 24h postchemotherapy. The resulting tissue was analysed for apoptosis, Ki67, ER and HER-2 using immunohistochemical
techniques. These data were then used to evaluate the relationship between these biological markers and response to chemotherapy
and overall survival. Response rate to chemotherapy in this group was 86%, 16 patients (25%) achieved a clinical complete response
and 41 (63%) a partial response. Prechemotherapy there was a significant correlation between Ki67 and apoptotic index (AI), r¼0.6,
(Po0.001). A significant rise in AI (Po0.001), and fall in Ki67 (P¼0.002) was seen 24h following chemotherapy. No relationship was
seen between pretreatment AI and clinical response, but higher Ki67 and growth index (Ki67/AI ratio, GI) did correlate with clinical
response (both r¼0.31, Po0.025). No correlation was seen between the change in AI or Ki67 at 24h and clinical response or
survival. Significant changes in apoptosis and proliferation can be demonstrated 24h following chemotherapy, but these changes do
not relate to clinical response or outcome in this study. Pretreatment proliferation and GI are however predictive of response to
chemotherapy in breast cancer.
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The use of primary or preoperative chemotherapy emerged as a
result of the good response rates seen with the treatment of locally
advanced breast cancers with chemotherapy (Swain et al, 1987;
Hortobagyi et al, 1988). In large but operable tumours, primary
chemotherapy has also shown high response rates, allowing more
conservative surgery. This reduces the need for mastectomy,
without affecting the local recurrence rate (Powles et al, 1995;
Smith et al, 1995; Fisher et al, 1997), and without compromising
survival (Fisher et al, 1998).
Another advantage of primary chemotherapy is that it provides
an in vivo model by which to study the effects of chemotherapy on
the primary tumour (Forrest et al, 1986). Adjuvant chemotherapy
has improved the outcome for women with breast cancer, through
large clinical trials (EBCTCG, 1998a). These trials, however, require
many years of follow-up and very large numbers of patients. New
approaches are needed to allow more rapid assessment of the large
number of new agents presently under development. Clinical
response to primary chemotherapy is associated with improved
survival, (Cameron et al, 1997; Bonadonna et al, 1998; Fisher et al,
1998), but this is an insensitive surrogate since the majority of
patients achieve a response. Biological markers, which are
predictive of response, might prove to be more sensitive short-
term surrogates of long-term outcome. If this were the case, the use
of these markers would substantially increase the speed of drug
development, and also tailor chemotherapy more effectively for the
individual patient.
Studies in primary chemoendocrine and endocrine therapy have
shown that early changes in proliferation, 14–21 days after starting
therapy, are significantly associated with clinical response.
(Dowsett et al, 1999). An increase in apoptosis following cytotoxic
chemotherapy occurs much earlier. In murine mammary tumours,
apoptosis has been demonstrated within 24–36h of cytotoxic drug
administration (Meyn et al, 1994, 1995), and in our earlier
preliminary clinical studies significantly increased apoptosis was
seen 24h after starting chemotherapy (Ellis et al, 1997). A small
study has indicated that an early increase in apoptosis as measured
in fine-needle aspirates (FNA) by flow cytometry was significantly
associated with clinical response in breast cancer, but this
methodology was noted to be complicated by problems of
precision (Chang et al, 1999). This study used core biopsy material
to evaluate the changes in apoptosis and proliferation 24h after
chemotherapy, and assessed the relationship of those changes with
clinical response and survival.
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Patient population
The study period was between February 1995 and March 2001.
Patients presenting to the Royal Marsden Hospital with nonmeta-
static primary breast cancer of 3cm or greater and to be treated
with primary chemotherapy were eligible for entry into this study.
The diagnosis of invasive breast cancer was made on 14-gauge core
biopsy in all patients prior to primary chemotherapy. Following
informed consent, patients entering the study had a further core
biopsy 24h after the start of the first course of chemotherapy, and
the material in both biopsies was analysed.
Treatment
Chemotherapy was anthracycline-based, except two patients who
received mitoxantrone. In all, 34 patients received doxorubicin-
based, and 30 patients epirubicin-based combination chemother-
apy. A total of 38 patients were entered into trials of primary
chemotherapy during the study period (Smith et al, 1995, 2000;
Eisen et al, 1998), others were treated with standard combination
chemotherapy. Tamoxifen was also prescribed to 49 (74%)
patients, 27 of whom started tamoxifen during the chemotherapy
(although after the 24h biopsy), and the remainder following
completion of chemotherapy. Chemotherapy was continued for six
cycles or until progression, when patients were considered for
surgery, which was usually lumpectomy or mastectomy with
axillary clearance.
Evaluation of tumour response
Response was assessed by bidimensional tumour measurements
before each cycle of chemotherapy. Response was defined as per
WHO criteria (Miller et al, 1981). Pathological evaluation of the
tumour postsurgery identified those who had no residual invasive
or in situ disease pathological complete response (pCR).
Laboratory methods
Core biopsies were taken after local anaesthetic infiltration of the
skin using a 14-gauge needle on a spring-loaded device. The
material obtained was formalin-fixed and paraffin-embedded.
Sections (3mm) were cut onto charged slides and left at 371C
overnight. These were examined by a Consultant histopathologist
(NN), for histological classification (NCGFBS, 1995) and grading
where possible (Bloom and Richardson, 1957). Immunohisto-
chemistry for Ki67, ER and HER-2 was performed using a standard
avidin–biotin complex technique according to the following
methodology, and apoptotic index (AI) assessed using Terminal
deoxynucleotidyltransferase-mediated d-UTP nick end labelling
(TUNEL) and in situ end-labelling (ISEL) techniques.
Ki67 Sections were dewaxed, hydrated and taken to water and
treated with hydrogen peroxidase to neutralise endogenous
peroxidases. After antigen retrieval by microwaving in citrate
buffer for 5min at full power (750W microwave), normal rabbit
serum at a dilution of 1:5 was applied. MIB1 primary antibody
(The Binding Site Ltd, UK) was used at a dilution of 1:50, and
incubated for an hour at room temperature. All dilutions and
washes were with phosphate-buffered saline (PBS). Rabbit
anti-mouse serum was applied followed by avidin–biotin
complex (ABC) (Dako, Denmark), which was developed by
diaminobenzene (DAB) (Sigma, USA), and counterstained with
haematoxylin.
HER-2 The sections were treated in a similar fashion as with the
MIB1 antibody, except that antigen retrieval was not required. The
primary antibody, ICR 12 (Gusterson et al, 1992) was used at a
dilution of 1:800, incubated for an hour at room temperature.
Oestrogen receptor (ER) The same staining procedure as for MIB1,
with microwave antigen retrieval. The primary antibody used was
ID5 (Dako) incubated at a dilution of 1:100 for 2h at room
temperature, according to previously validated conditions (Saccani
Jotti et al, 1994).
Apoptotic index In situ end labelling (ISEL) uses biotin-16-dUTP
(Boehringer Mannheim) plus the Klenow fragment of Escherichia
coli DNA polymerase 1 (Pharmacia) (Wijsman et al, 1993).
Terminal deoxynucleotidyltransferase-mediated d-UTP nick end
labelling (TUNEL) technique is modified from Gavrieli et al (1992).
Both these techniques have been used by our laboratory and have
shown equivalent results in breast cancer sections (Mainwaring
et al, 1998).
Scoring
All sections were coded and scored blind to time of biopsy,
treatment and clinical outcome by PAE, CDA and MP. Sections
were examined under a standard light microscope using a  40
objective and a 10 10 eye piece incorporating a graticule.
Invasive breast cancer cells only were counted. Ki67 score was
defined as a percentage of total number of tumour cells with
nuclear staining to the MIB1 antibody over 10 high power fields
( 40). A tumour was defined as HER-2 positive by the presence of
the characteristic membrane staining in over 10% of the tumour
cells. The AI was a percentage score of apoptotic cells from a total
of 3000 malignant cells. Unstained apoptotic cells were included if
they showed classical morphological features of apoptosis,
cytoplasmic condensation and chromatin clumping (Wyllie et al,
1980). Apoptotic bodies not obviously associated with an apoptotic
cell were included in the count only when present as clumps.
Oestrogen receptor was assessed either with a Histo-score (H-
score) or using a Quickscore that has been previously validated
against H-score in breast cancer sections. Oestrogen receptor
positive was defined as an H-score of 420 (Detre et al, 1995).
Statistical analysis
Nonparametric statistics were used. The changes in AI and
proliferation during the first 24h of chemotherapy were analysed
using the Wilcoxon signed-rank test. The relationship at baseline
between AI and MIB1 scores was assessed using the Spearman
rank correlation, as was the association between biological
markers and response. Kaplan–Meier curves were used for
survival analysis. No formal powering of the study was conducted,
but with 66 patients it would be possible to detect a correlation of
0.40 or greater with 90% power.
Ethical
This study was approved by the Research and Ethics Committee of
the Royal Marsden NHS Trust. All patients gave written informed
consent.
RESULTS
Clinical results
A total of 108 patients consented to study entry and had a repeat
core biopsy 24h after starting chemotherapy. In all, 66 patients had
sufficient invasive tissue in both biopsies to be used for analysis of
the biological markers, although seven of these did not have
enough material to be tested for all parameters. The characteristics
of the study population are given in Table 1.
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Table 2. In all, 57 patients (86%) responded to treatment, 16 (25%)
achieving a clinical complete remission (cCR) and 41 (63%) a
partial response (PR). One patient was not evaluated for response
due to death early on treatment. Following chemotherapy, 12
patients did not have surgical treatment: one refused, two
remained inoperable and nine patients achieved a cCR and had
radiotherapy alone, as part of a separate research study. As
expected, this overall pCR rate of 7.5% is lower than the 16% seen
in the major primary chemotherapy trial recruiting in our
institution during the study period (Smith et al, 2000). This was
clearly influenced by the nine patients (18%) with a cCR who did
not have any surgery following chemotherapy. Median follow-up
was 36 months (1–74) and there were 21 relapses and 15 deaths.
Progression-free and overall survival figures are detailed in Table 2.
Biological results
Apoptosis and proliferation Prior to treatment there was a highly
significant positive correlation between proliferation, as measured
by Ki67 and AI samples (rho¼0.60, Po0.001), Figure 1. Tumour
grade was also significantly correlated with both apoptosis and
proliferation pretreatment, Po0.001. Median AI prechemotherapy
was 0.9 (interquartile range (IQ), 0.5–1.5) and at 24h postche-
motherapy this had increased significantly to 1.60 (IQ 1.0–2.9,
Po0.001), Figure 2A. The median Ki67 score pre-chemotherapy
was 28.5 (IQ 16.1–43.9) and 24h following chemotherapy this had
fallen significantly to 17.6 (IQ 8.7–26.8, P¼0.002), Figure 2B.
In addition to assessing the impact of chemotherapy on Ki67
and AI individually, the effect on the Ki67/AI ratio, a parameter
which we have described as a growth index (GI) (Harper-Wynne
et al, 2002) was assessed. There was a significant fall in GI at 24h,
from 28.5 (IQ 19.9–43.5) to 11.5 (IQ 6.0–25.2, Po0.001),
Figure 2C. It was notable that while Ki67 increased in 20 patients
and AI decreased in 10 patients, only five patients showed an
increase in GI.
The changes in AI and Ki67 are shown according to HER-2 and
ER status in Table 3. There were no significance differences in the
changes in apoptosis and proliferation seen with chemotherapy
according to HER-2 status, but those patients who were ER-
positive had a greater proportional fall in proliferation post-
chemotherapy compared with ER-negative patients (P¼0.006).
Relationship of biological indices with clinical response
Pretreatment indices There was no relationship between pre-
treatment AI and overall clinical response, r¼ 0.04, but higher
levels of proliferation pretreatment correlated with increased
clinical response, r¼ 0.31, Po0.025. Tumour grade was not
correlated with overall clinical response, but grade 3 tumours had
a greater rate of cCR rate than grade 2, P¼0.007. A significant
relationship was also seen between the GI pretreatment and the
clinical response to treatment, r¼0.31, Po0.025. A significant
correlation between both pretreatment proliferation and GI
(Po0.025) with clinical response was also seen in the subgroup
of patients treated with chemotherapy alone. These were defined as
no concomitant tamoxifen or ER-negative patients who received
Table 1 Demographics and patient characteristics
Characteristic No. of patients (n¼66)
Age (years)
Median 48 (32–63)
Menopausal status
Premenopausal 39 (59%)
Perimenopausal 3 (5%)
Postmenopausal 24 (36%)
Tumour stage
T-2 29 (44%)
T-3 26 (39%)
T-4 operable 1 (2%)
T-4 inoperable 10 (15%)
Tumour size (cm)
Median 5.7 (3–20)
Histology
Ductal 56 (84%)
Lobular 8 (12%)
Ductal+lobular 1 (2%)
Mucinous 1 (2%)
Grade
Grade1 0 (0%)
Grade 2 29 (44%)
Grade 3 34 (51.5%)
Unknown 3 (4.5%)
ER status
Positive 43 (65%)
Negative 23 (35%)
HER-2 status
Positive 18 (27%)
Negative 48 (73%)
Table 2 Overall response to treatment and outcome
No. of patients
Response to primary chemotherapy n¼65
Complete response 16 (24%)
Partial response 41 (62%)
Overall response rate 57 (86%)
No change 6 (9%)
Progressive disease 2 (3%)
Surgery n¼66
Conservative 36 (55%)
Mastectomy 17 (26%)
No surgery 13 (19%)
Pathological status at surgery n¼66
Residual invasive disease 46 (70%)
Complete pathological response 5 (7.5%)
DCIS only 3 (4.5%)
Overall progression-free survival n¼66
1 year 87%
2 years 74%
3 years 65%
Overall survival n¼66
1 year 93%
2 years 83%
3 years 77%
DCIS¼ductal carcinoma in situ.
Pretreatment AI and Ki67
rho=0.60, P<0.001
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Figure 1 Correlation of pretreatment Ki67 and AI scores. Each data
point represents the scores for an individual tumour (rho¼0.60,
Po0.001).
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negligible. No correlation was seen with pretreatment AI and
clinical response in this subgroup.
Changes at 24h There was no significant relationship seen
between clinical response and the biological changes 24h after
chemotherapy for either AI, Ki67 or GI, Figure 3. This applied to
either the whole group or that of the chemotherapy alone group.
Relationship of biological indices with progression-free
and overall survival
On univariate analysis, no relationship was seen between
pretreatment AI, Ki67 or GI (assessed as high or low values,
above or below the median) with progression-free or overall
survival. Similarly, there was no significant relationship between
the changes in these parameters seen at 24h after chemotherapy
with progression-free or overall survival. Although those patients
with a lower pretreatment GI appeared to have an improved overall
survival this was not significant, P¼0.2, Figure 4.
DISCUSSION
In this study, we have demonstrated a significant relationship
between AI and Ki67 in breast tumours prior to the initiation of
therapy. This is consistent with our previous work (Ellis et al,
1998) and that of others (Lipponen et al, 1994; van Slooten et al,
1998), indicating that tumours with a high rate of apoptosis are
also rapidly proliferating. Apoptotic index and Ki67 also correlated
positively with high pathological grade. Apoptotic index has been
previously shown to be associated with p53 overexpression, but
inversely with bcl-2 and ER (Lipponen et al, 1994; Hori et al, 1997;
Rochaix et al, 1999). A high proliferation rate in breast tumours is
associated with a poorer prognosis (Meyer and Lee, 1980;
Silvestrini et al, 1985) as is p53 expression (Silvestrini et al,
1993), whereas ER overexpression is associated with a more
favourable prognosis (EBCTCG, 1998b). One might also expect AI
to be associated with a poorer outcome, but AI has not been found
to have independent prognostic value (Lipponen et al, 1994).
Pretreatment levels of proliferation positively correlated with
clinical response. This is consistent with other studies, either using
the MIB1 antibody or S-phase fraction (Bonetti et al, 1996;
Chevillard et al, 1996; MacGrogan et al, 1996). Ki67 is an antigen
that binds to a protein expresssed in late G1-, S-, G2-, and M-phase
of the cell cycle, and although most cytotoxic drugs have
maximum effect in S-phase, some also act in other phases of the
cell cycle, and therefore this finding would be compatable with the
biology (Boyer and Tannock, 1998). It is notable, however, that
despite most studies concurring that high proliferation is
associated with good response to chemotherapy, this same group
of patients, as mentioned above, is known to have a poor long-
term outcome (Ravaioli et al, 1998). A similar type of relationship
with outcome is seen with tumour grade. This may reflect a single
biological relationship, since mitotic rate is also a component of
tumour grade. There was no relationship between pretreatment AI
and clinical response, but the GI, which summates the opposing
effects of apoptosis and proliferation, did show a relationship with
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Figure 2 The percentage change in Al (A), Ki67 (B) and GI (C) in core
biopsies 24h after chemotherapy (n¼60). The scores have been divided
to show a fall to the left of the line and a rise to the right, (A) AI, Po0.001,
(B) Ki67, P¼0.002, (C)G IPo0.001).
Table 3 Percentage change from pretreatment levels in AI, Ki67 and GI
after 24h of chemotherapy
AI Ki67 GI
All
N6 0 6 4 5 8
Median +81.1  17.0  53.4
IQ range +12.7 to +205.65  50.0 to +8.5  76.5 to  27.4
ER positive
N3 8 43 38
Median +82.5  26.1  62.6
IQ range +4.6 to +237.5  55.7 to  1.11  80.2 to  29.4
ER negative
N2 2 21 20
Median +81.0  3.2
a  31.3
IQ range +29.8 to +167.5  26.8 to +33.0  60.6 to  21.4
HER-2 positive
N1 5 1 8 1 5
Median +33.1  12.9  37.4
IQ range +10.8 to +154.6  37.3 to +14.0  77.3 to  4.7
HER-2 negative
N4 5 4 6 4 3
Median +100.0  19.4  54.0
IQ range +14.85 to +221.4  54.6 to +9.3  76.3 to  28.9
aChange in Ki67 between ER-positive and ER-negative tumours, P¼0.006.
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no greater than that with Ki67 alone. Although biological markers
pretreatment predicted clinical response, no relationship was seen
with disease-free or overall survival.
The data from this study confirm our earlier findings of a
significant increase in apoptosis following chemotherapy and
extend them with the observed significant fall in proliferation at
24h. Since changes in apoptosis and/or proliferation are requisites
for changes in tumour growth rate, their early measurement
during treatment has been investigated on the basis that this might
enable the prediction of eventual clinical response and long-term
benefit from treatment. A small pilot study of 15 patients by Chang
et al (2000) using FNA and different laboratory methods did find a
significant relationship between early change in apoptosis (at 24–
72h following treatment) and clinical response (Chang et al, 2000).
We were unable to confirm such a relationship between changes at
24h and clinical response.
The timing of sampling post chemotherapy may be important in
quantifying the increase in AI: the Chang study sampled at either
24 and/or 72h postchemotherapy, and used a mean of both
measurements when more than one was available. A recent study,
again with 15 patients took biopsies at 24 and 48h, and also failed
to show a relationship between apoptosis at 24h following
chemotherapy, but demonstrated a relationship at 48h. They
noted marked variations though, with one tumour showing a rise
in apoptosis at 24h, but not at 48h (Davis et al, 2003). It seems
likely that the time of peak increase in apoptosis may vary between
patients.
The biopsy at 24h in our study was taken after starting
chemotherapy alone, but tamoxifen was subsequently given to
some patients that may have had an effect on tumour response and
therefore possibly confounded any relationship between che-
motherapy-induced apoptosis and clinical response. We therefore
performed an analysis on the data from patients who did not
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Figure 3 Scattergram illustrating the relationship between change in AI
(A), Ki67 (B), GI (C) and clinical response. Each dot is a value for a
tumour and the horizontal line is the median value. PD, progressive disease;
NC, no change
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negative (where the benefit of any tamoxifen, even if given would
have been expected to be negligible). Even in this subgroup no
relationship between changes in AI or proliferation at 24h and
clinical response was seen. A recent study, however, has shown no
difference in the response rate to primary chemotherapy with the
addition of tamoxifen (von Minckwitz et al, 2001).
Our study was small, but the number of samples would have
enabled a correlation of 0.40 to be detected in 90% of cases. To be
clinically useful in predicting response in individual patients, a
correlation would need to be substantially greater, and therefore
this study would have been able to detect a correlation of clinical
utility. Only 62% of patients had enough tissue in the either biopsy
to allow assessment of biological markers by immunohistochem-
istry, principally due to the large numbers of tumour cells needed
to evaluate AI with acceptable precision. This introduces a
sampling bias, the data being only applicable to the subgroup
with repeatedly cellular samples. The Chang study also noted this
problem using FNAs, only 15 out of 28 patients (53%) having
enough material for biological analysis. A 50–60% success rate
also limits the widespread clinical utility of these tests.
Given that there were significant changes in both proliferation
and apoptosis after 24h, which are both likely to contribute to
eventual tumour response, we assessed the relationship of GI with
clinical response. It was notable that although there were 20
tumours that showed an increase in Ki67 and 10 that showed an
decrease in AI, only five showed an increase in the growth index,
indicating that the therapy had a beneficial overall effect on
tumour growth in 90% of tumours. While the GI pretreatment
correlated with response, changes in GI 24h after chemotherapy
had no predictive value for response. Thus, while this index may
be useful as a guide to overall changes in tumour dynamics, it does
not appear to have utility for response prediction.
One of the most significant predictors of relapse-free survival
following primary chemotherapy has been shown to be a pCR
(Fisher et al, 1998). In our study not all the patients proceeded to
surgery, and most of these were patients who achieved a cCR. This
confounded the valid assessment of biomarker analysis in relation
to pCR.
The lack of a correlation of these early markers with response to
chemotherapy or with clinical outcome is disappointing in view of
the clear biological rationale for such a relationship and possible
reasons for this need to be considered. It should also be noted that
a given reduction in proliferation or increase in cell death might
lead to regression of a slowly growing tumour, but only slow the
growth of a rapidly growing tumour. Thus it may be over
simplistic to expect a close relationship between change in these
parameters and response measured clinically. Other measurements
of response were not performed in this study. Mammography has
been shown to be a poorer than clinical measurement (Florentino
et al, 2001), but ultrasound maybe more useful and could have
allowed measurement of volume changes, which has been used in
other studies with primary endocrine treatment (Miller et al, 2001;
Harper-Wynne et al, 2002).
Overall we believe this area merits further evaluation, and the
study of noninvasive techniques, such as PET may eventually be
applicable very early after starting chemotherapy. Also the use of
newer techniques such as DNA microarray may improve the
predictability of response by combining the change in expression
of larger numbers of genes (Assersohn et al, 2002). The analysis
growth parameter changes at 24h seem to have little clinical utility
for predicting individual patient response, and measurement at
later time points (e.g., 14 out of 21 days) may hold greater promise
(Dowsett et al, 1999).
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